Phase 2 N=23 Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Lung Cathelicidin Level at 8 Weeks — -65.5 pg/mL — p=0.21
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,044 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 9.99; 11.60; 7.13; 7.36 months — p== 0.872
Phase 2 N=39 Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Malignant Glioma
Primary: Six-month Progression-free Survival (PFS6) — 14.3; 5; 14.3; 40 percentage of participants
Phase 2 N=127 Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis (NASH)
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 70.6; 71.4; 61.5 percentage of participants
Phase 2 N=31 Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2 · Obesity
Primary: Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril…
Phase 2 N=16 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
HIV-1 Infection
Primary: Number of Participants With Virologic Rebound at 8 Weeks After Interruption of Antiretroviral Therapy — 4; 3 Participants
Phase 2 N=68 Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Recurrent Breast Carcinoma · Stage IV Breast Cancer
Primary: PFS — 3.5 months
Phase 2 N=80 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=73 Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
Atopic Dermatitis
Primary: The Number of Subjects Experiencing AEs — 11; 14; 12 participants
Phase 2 N=17 Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Non-Small Cell Lung Cancer
Primary: Radiographic Response Rate — 1; 6; 10 Participants
Phase 2 N=88 Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Non-small Cell Lung Cancer
Primary: Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT) — 0; 0 Participants
Phase 2 N=204 Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Carcinoma, Merkel Cell
Primary: Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 — 10; 19; 9; 0…
Phase 2 N=76 Nilotinib in Parkinson's Disease
Parkinson Disease
Primary: Tolerability of Nilotinib Over Placebo — 21; 19; 20 Participants — p=0.3626
Phase 2 N=125 Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal
Pain · Urinary Stone · Urinary Calculi
Primary: Number of Participants With Unscheduled Return to Clinic or Emergency Room — 8; 1 Participants